Patricia Adams - Aptinyx President
| APTXDelisted Stock | USD 0.07 0.01 16.67% |
President
Ms. Patricia Adams is Vice President Human Resources and Administration of the Company. Ms. Adams is vice president of human resources and administration at Aptinyx. She has over 24 years of experience in the healthcare industry, which includes 15 years in human resources. Previously, Ms. Adams was vice president of human resources at Naurex. Prior to joining Naurex, she served as senior director of human resources for Durata Therapeutics where she managed HR planning and operations in support of the commercial launch of Dalvance. Ms. Adams has also led human resources functions at SagePath Medical, BioSante Pharmaceuticals, Lundbeck Inc., and Takeda Pharmaceuticals North America
| Phone | 847 871 0377 |
| Web | https://www.aptinyx.com |
Aptinyx Management Efficiency
The company has return on total asset (ROA) of (0.5135) % which means that it has lost $0.5135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3806) %, meaning that it created substantial loss on money invested by shareholders. Aptinyx's management efficiency ratios could be used to measure how well Aptinyx manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.11 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. Aptinyx has a current ratio of 15.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Aptinyx until it has trouble settling it off, either with new capital or with free cash flow. So, Aptinyx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aptinyx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aptinyx to invest in growth at high rates of return. When we think about Aptinyx's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Jacqueline Papkoff | Assembly Biosciences | 61 | |
| David Houck | Assembly Biosciences | 61 | |
| Uri Lopatin | Assembly Biosciences | 45 | |
| Timothy Keutzer | Spero Therapeutics | 56 | |
| James Windsor | Aileron Therapeutics | 57 | |
| Manuel Aivado | Aileron Therapeutics | 47 | |
| Kira Nelson | Aileron Therapeutics | 48 | |
| Brian Windsor | Aileron Therapeutics | 57 | |
| Janet LeeSheriff | Instil Bio | N/A | |
| Donald Dougherty | Aileron Therapeutics | 58 | |
| Srinivas Subramanian | Avenue Therapeutics | 53 | |
| Pinaki Niyogy | Instil Bio | 46 | |
| Lloyd Rowland | CytomX Therapeutics | 61 | |
| Steven Knox | Assembly Biosciences | N/A | |
| Allen Annis | Aileron Therapeutics | 51 | |
| Cynthia Ladd | CytomX Therapeutics | 61 | |
| Nick Galli | CytomX Therapeutics | N/A | |
| Evan Lippman | Aileron Therapeutics | N/A | |
| Christopher Keenan | CytomX Therapeutics | N/A | |
| Stephen Garbacz | Spero Therapeutics | 56 | |
Management Performance
| Return On Equity | -1.38 | |||
| Return On Asset | -0.51 |
Aptinyx Leadership Team
Elected by the shareholders, the Aptinyx's board of directors comprises two types of representatives: Aptinyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptinyx. The board's role is to monitor Aptinyx's management team and ensure that shareholders' interests are well served. Aptinyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptinyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathryn King, VP Operations | ||
| Torsten Madsen, Chief Medical Officer | ||
| Wilbur Gantz, Independent Chairman of the Board | ||
| David Houck, Chief Development Officer | ||
| Elisha Gould, Independent Director | ||
| Robert Hombach, Independent Director | ||
| Patrick Flavin, Sr Relations | ||
| Ashish Khanna, Chief Business Officer | ||
| Harald MD, VP Affairs | ||
| Henry Gosebruch, Independent Director | ||
| MD BCh, Pres CEO | ||
| Patrick Enright, Independent Director | ||
| Patricia Adams, Vice President - Human Resources and Administration | ||
| Joseph Moskal, Chief Scientific Officer | ||
| Norbert Riedel, President CEO, Director | ||
| James Topper, Independent Director | ||
| Molly Dir, VP HR | ||
| Tim Noffke, VP Staff | ||
| Andrew Kidd, Chief Commercial Officer | ||
| Adam Koppel, Independent Director |
Aptinyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptinyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (25.91 M) | |||
| Shares Outstanding | 67.72 M | |||
| Shares Owned By Insiders | 13.12 % | |||
| Shares Owned By Institutions | 42.96 % | |||
| Number Of Shares Shorted | 2.23 M | |||
| Price To Earning | (5.61) X | |||
| Price To Book | 0.33 X | |||
| Price To Sales | 45.33 X |
Pair Trading with Aptinyx
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptinyx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptinyx will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptinyx Stock
| 0.87 | PME | Pingtan Marine Enterprise | PairCorr |
Moving against Aptinyx Stock
| 0.85 | IBM | International Business Report 17th of April 2024 | PairCorr |
| 0.83 | PG | Procter Gamble Earnings Call This Week | PairCorr |
| 0.83 | AXP | American Express Earnings Call This Week | PairCorr |
| 0.81 | TRV | The Travelers Companies Earnings Call Tomorrow | PairCorr |
| 0.73 | DIS | Walt Disney Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to Aptinyx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptinyx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptinyx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptinyx to buy it.
The correlation of Aptinyx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptinyx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptinyx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptinyx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Aptinyx Stock
If you are still planning to invest in Aptinyx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aptinyx's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |